Table of Contents Table of Contents
Previous Page  10 / 154 Next Page
Show Menu
Previous Page 10 / 154 Next Page
Page Background

Speaker’s Biographies

Tamas Fulop

Université de Sherbrooke




Sherbrooke, Qc



Tamas Fulop, MD, PhD, is Professor of Medicine and Geriatrics, and Senior Researcher at the Research Center on Aging,

University of Sherbrooke, Québec, Canada. He is the deputy director of the Research Center on Aging and member of

the Graduate Immunology Programme. He was the President of the Société Québecoise de Gériatrie from 2007–2012. He

has directed the Biology Research Programme of the Research Center on Aging for more than 10 years. He obtained his

MD degree at Geneva University. He received his PhD in Biochemistry and Immunology from the Hungarian Academy

of Sciences and was a post-doctoral fellow at University Paris XII in Biochemistry. Dr. Fulop’s NSERC and CIHR

funded research since 1994 is focused on immune response changes in T cells and neutrophils and the mechanism of

inflammation with aging and age-related diseases in humans: Dementia, cardiovascular diseases. More specifically his

research is directed to the elucidation of the signal transduction changes in immune cells with specific focus on lipid

rafts. He has authored more than 230 publications. He is recipient of the Presidential Award of the IAGG and fellow of

the GSA since 2001. He served on the executive committee and participated in the organization of three IAG congresses.

He served on the GSA Publications Committee and BS executive committee. He is on the editorial boards of Pathology

Biology, Immunity and Aging, European Geriatric Medicine, Journal of frailty and Aging, Journal of Geriatrics and

Palliative Care, Gerontology and was Section Editor of the BMC open access journal Immunity and Aging. He is the

editor-in-chief of the Interdisciplinary Topics in Gerontology. He is co-director of the undergraduate geriatric teaching


Speaker Abstract(s): S12

Paolo Ghia

Università Vita-Salute San Raffaele, Division of Experimental Oncology, Milano, Italy

Paolo Ghia received his MD from the University of Torino, Italy, followed by a residency in Internal Medicine. He

received his PhD working at the Basel Institute for Immunology, Basel, Switzerland, where he studied the development

of normal human B lymphocytes. He moved to the Dana-Farber Cancer Institute, Harvard Medical School, Boston,

where he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly

of follicular lymphoma.

He is now working in Milano, as Associate Professor in Internal Medicine at the Università Vita-Salute San Raffaele;

and Deputy Chairman of the Division of Experimental Oncology, at the San Raffaele Scientific Institute. He is Head of

the Laboratory of B-Cell Neoplasia and former Scientific Coordinator of the Clinical Unit of Lymphoid Malignancies. He

is now Director of the Strategic Program on CLL, where he is National Coordinator or Principal Investigator in over 20

clinical trials in CLL and related disorders, including phase 1 studies.

His research interest is the study of the molecular and cellular mechanisms acting in the natural history of Chronic

Lymphocytic Leukemia (CLL), including Monoclonal B-cell Lymphocytosis (MBL). On these topics he has published over

170 manuscripts in peer-reviewed journals.

He is President of the European Research Initiative on CLL (ERIC), collaborating to the guidelines for the detection

of Minimal Residual Disease (MRD) for the analysis of the mutational status of the immunoglobulin genes and of the

TP53 gene mutations. He is also a member of the WHO Clinical Advisory Committee for Lymphocytic and Histiocytic

Malignancies for the topic Chronic Lymphocytic Leukemia, MBL, and PLL and associate Editor for CLL at Haematologica,

the official Journal of the European Hematology Association (EHA).

Speaker Abstract(s): S13

Marine Gilabert

Medical Oncology, Paoli Calmettes Institute, Marseille, France

Dr. Marine Gilabert is an associate professor and a medical oncologist from Marseille, France, Aix-Marseille University.

Her medical training and Ph.D was completed at Paoli-Calmettes Institute, Marseille, France in 2011 and 2014

respectively. She received a prestigious Kate McGarrigle Fundation research fellowship which she was undertaking at

Jewish General Hospital, McGill University, Montreal, Canada in 2015. Her main interests are gastrointestinal and

hepatopancreatobiliary cancers. She has been significantly involved in Phase I, II and III clinical trials and is principal

investigator of a numerous translational research.

Speaker Abstract(s): S14

Cesare Gridelli

“S.G. Moscati” Hospital, Medical Oncology, Avellino Italy

Cesare Gridelli, MD, is currently Chief of Division of Medical Oncology at the “S.G. Moscati” Hospital, Avellino (Italy).

He has been from December 2003 to February 2016 Director of Department of Oncology/Hematology at the same

institution. He earned his medical degree and residencies in Internal Medicine and then in Medical Oncology at the

“Federico II” University of Naples (Italy). Since 1993 Vice-Chief of Division of Medical Oncology B, National Cancer

Institute of Naples. Since 2001 Chief of Day Hospital Chemotherapy Unit at the same Institute. His areas of expertise

are lung cancer and cancer in the elderly. He is deeply involved in the clinical development of new anticancer targeted